Skip to main content
OpenTrials
Completed

NCT Number: NCT06444477

Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer

The association between hematologic malignancies and ITP is well described, but this link is much less clear with solid cancers. In cases of ITP associated with cancers, specific cancer treatment can lead to remission or even cure of ITP. Thus, our hypothesis was that chronic expression of GPIIB by tumor cells could have initiated an autoimmune loop against GPIIB, leading to the onset and perpetuation of ITP.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Immune Thrombocytopenia Autoimmune Diseases Blood Coagulation Disorders Blood Platelet Disorders Cancer Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhage Hemorrhagic Disorders Immune System Diseases Immune Thrombocytopenic Purpura Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms Purpura Purpura, Thrombocytopenic Purpura, Thrombocytopenic, Idiopathic Signs and Symptoms Skin Manifestations Thrombocytopenia Thrombotic Microangiopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

AP-HP Hôpital Jean Verdier service de médecine interne, Bondy, France

Loading trial locations.

About this study

Autoimmune thrombocytopenia, also known as immune thrombocytopenic purpura (ITP), is a rare autoimmune disease characterized by platelet destruction and impaired production, posing a life-threatening risk due to bleeding complications. The pathophysiology of ITP involves complex mechanisms, including both defective platelet production and auto-reactivity of B and T lymphocytes leading to the production of autoantibodies against platelets, found in 35 to 55% of cases. Additionally, in the context of neoplasia, some patients may develop varying degrees of thrombocytopenia, exacerbating morbidity and mortality. A multicenter, retrospective study will collect data from routine care, including birth date, gender, biological parameters related to ITP, dates of treatment initiation and diagnosis of ITP and cancer, types of treatments, and outcomes such as survival or death, without additional medical interventions or appointments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients with a definite diagnosis of both ITP and cancer;
  • Synchronous diagnosis of ITP and cancer;
  • Onset of ITP occurring 6 months before or after the diagnosis of cancer.

Exclusion criteria

  • None

Treatment and study plan

ITP and cancer

Other

ITP and cancer

Primary outcomes

  1. Remission rate of ITP at 6 months after specific cancer treatment

    Time frame: At baseline (Day 0)

Secondary outcomes

  1. All-cause mortality

    Time frame: At baseline (Day 0)

  2. Side effects related to ITP and its treatment

    Time frame: At baseline (Day 0)

  3. Side effects related to its treatment

    Time frame: At baseline (Day 0)

  4. Clinical description of the characteristics of ITP associated with a diagnosis of solid cancer

    Time frame: At baseline (Day 0)

  5. Biological description of the characteristics of ITP associated with a diagnosis of solid cancer

    Time frame: At baseline (Day 0)

  6. Demographic description of the characteristics of ITP associated with a diagnosis of solid cance

    Time frame: At baseline (Day 0)

  7. Therapeutic description of the characteristics of ITP associated with a diagnosis of solid cance

    Time frame: At baseline (Day 0)

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Acronym: MATAC

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 5, 2024
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.